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DOI 10.1016/j.ccr.2011.08.023SUMMARYA genomic signature designed to assess the activity of the estrogen-related receptor alpha (ERRa) was used
to profile more than 800 breast tumors, revealing a shorter disease-free survival in patients with tumors exhib-
iting elevated receptor activity. Importantly, this signature also predicted the ability of an ERRa antagonist,
XCT790, to inhibit proliferation in cellular models of breast cancer. Using a chemical genomic approach, it
wasdetermined thatactivationof theHer2/IGF-1RsignalingpathwaysandsubsequentC-MYCstabilizationup-
regulate the expression of peroxisome proliferator-activated receptor gamma coactivator-1 beta (PGC-1b), an
obligate cofactor for ERRa activity. PGC-1b knockdown in breast cancer cells impaired ERRa signaling and
reducedcell proliferation, implicating a functional role for PGC-1b/ERRa in the pathogenesis of breast cancers.INTRODUCTION
The estrogen-related receptor alpha (ERRa) is an orphan
member of the nuclear hormone receptor superfamily of tran-
scription factors for which an endogenous ligand has yet to be
defined (Gigue`re et al., 1988). The high degree of structural simi-
larity between ERRa and the estrogen receptor (ER), particularly
in the DNA binding domain, has led to the speculation that the
transcriptomes of these two receptors may overlap. Given the
established role of estrogens in breast cancer, it was not sur-
prising that there is considerable interest in determining the
extent to which ERRa impinges on ER signaling and contributes
to the pathogenesis of breast cancer. It was significant, there-
fore, that the expression of ERRa, in breast cancer was shown
to correlate with unfavorable clinical outcomes in a manner
that was independent of ER status (Ariazi et al., 2002; Suzuki
et al., 2004). Further, higher expression of ERRa was observed
in ER-negative breast cancers and its expression is also associ-
ated with that of Human Epidermal Growth Factor Receptor 2
(Her2). These observations suggest that ERRa is not merely
a substitute for, or a modulator of, ER function but rather has
distinct activities that may contribute to the pathogenesis ofSignificance
Overexpression of ERRa has been correlated with progression
a genomic approach, we defined specific aspects of the activit
in multiple cohorts of breast cancer patients. Importantly, cellu
more sensitive to growth inhibition by an ERRa antagonist. Thi
aggressive tumors that currently have limited therapeutic opti
500 Cancer Cell 20, 500–510, October 18, 2011 ª2011 Elsevier Inc.breast cancer. This conclusion was reinforced by the results of
recently published chromatin immunoprecipitation combined
with microarray (ChIP-chip) analyses of breast cancer cells that
revealed relatively minor overlap in the transcriptomes of ER
and ERRa. Indeed, these studies indicated that the majority of
the genes that are regulated by ERRa are distinct from those
controlled by ER (Deblois et al., 2009; Dufour et al., 2007).
ERRa functions downstream of the peroxisome proliferator-
activated receptor gamma coactivator-1 alpha and beta (PGC-
1a and PGC-1b) and controls the expression of genes involved
in the tricarboxylic acid (TCA) cycle, oxidative phosphorylation
(OXPHOS), and lipid metabolism (for review, see Lin et al.,
2005). By regulating these genes, ERRa controls energy metab-
olism in the liver, skeletal muscle, heart, and adipose tissue
(Huss et al., 2004, 2007; Kamei et al., 2003; Mootha et al.,
2004; Villena et al., 2007). Although it is unclear whether ERRa-
dependent regulation of cellular metabolism plays a role in the
pathogenesis of breast cancer, it is worth noting that enzymes
involved in glycolysis, TCA cycle, and OXPHOS have been found
to be upregulated in models of breast cancer brain metastases
(Chen et al., 2007). Aside from the ability to regulate energy
metabolism, ERRa regulates VEGF expression in breast cancerof breast and ovarian cancers in several small studies. Using
y of this receptor that track with shorter disease-free survival
lar models of breast cancer exhibiting high ERRa activity are
s finding highlights a promising treatment strategy for those
ons.
Figure 1. Expression of ERRa-Regulated Genes
Clusters Tumor Samples into Clinically Distinct
Groups
(A and C) Unsupervised hierarchical clustering of tumor
samples in two clinical data sets using 448 ERRa-regu-
lated probe sets. The order of probe sets in the Uppsala
data set was fixed to match that in the Rotterdam clus-
tering diagram to reveal common patterns of gene regu-
lation in these twoclinical data sets. Hierarchical clustering
revealed that the expression pattern of ERRa-regulated
genes in clinical samples separates the genes into 4
different clusters (boxed and labeled 1, 2, 3, and 4).
(B and D) Relapse-free survival was plotted for patients in
the right branch versus patients in the left branch. Kaplan-
Meier curves were generated using GraphPad Prism and
p value was determined by log rank test.
See also Figure S1.
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ERRa Is a Therapeutic Target in Breast Cancerand skeletal muscle cells, interacts with and modulates HIF1
activity, and is required for the migration of MDA-MB-231 breast
cancer cells in vitro (Ao et al., 2008; Arany et al., 2008; Chinsom-
boon et al., 2009; Stein et al., 2008, 2009). Together, these data
suggest that ERRa is a key regulator of several ER-independent
processes of importance in breast cancer. It is not clear, how-
ever, which specific aspects of ERRa biology are most relevant
to the pathogenesis of breast cancer.
Recent studies using siRNAs and small-molecule antagonists
have demonstrated that ERRa is required for the growth of both
ERa-positive and ERa-negative breast cancer cells when as-
sayed in vitro or when propagated as xenografts (Ao et al.,
2008; Bianco et al., 2009; Chisamore et al., 2009; Stein et al.,
2008). Whereas these findings provide the rationale for the
exploitation of ERRa as a therapeutic target, it remains unclear,
absent evidence for the existence of a bone fide small molecule
ligand, how the transcriptional activity of this receptor is regu-
lated in cancer. Thus, the primary objectives of this study were
to define the processes that impinge upon and regulate ERRa
transcriptional activity in breast cancer cells and to define the
processes downstream of the receptor that contribute to breast
cancer pathogenesis.
RESULTS
The Expression of a Subset of ERRa-Regulated Genes
Correlates with Relapse-Free Survival in Breast Cancer
Patients
The expression of ERRa has been shown to correlate with an
unfavorable clinical prognosis in breast cancer (Ariazi et al.,
2002; Suzuki et al., 2004). However, the role(s) of this receptor
in the pathogenesis of this disease or its potential utility as a ther-
apeutic has not been established. To address these issues, we
first examined whether ERRamRNA expression itself is a robust
predictor of patient survival in six clinical breast tumor microar-
ray data sets. Surprisingly, only one data set showed a statisti-
cally significant correlation between high ERRa expression and
shorter disease survival (data not shown). Because ERRa is
a transcription factor and its activity is regulated atmultiple levels
(i.e., expression of its required coactivators), we reasoned that
a genomic signature derived from ERRa-regulated genes mightCbe a more appropriate way to evaluate the pathological signifi-
cance of ERRa activity in clinical samples.
As a first step in the development of a genomic predictor of
ERRa activity, wedefined the spectrumof ERRa-regulated genes
in human primarymammary epithelial cells (hMECS), a nontrans-
formedcellular background, to avoid introduction of bias by other
dysregulated oncogenic pathways. Unlike most other nuclear
receptorswhose transcriptional activity canbe regulatedbysmall
molecule ligands, the activity of ERRa appears to be controlled at
the level of coactivator availability and/or posttranslational modi-
fications of the ERRa protein itself. Thus, in order to generate a
robust genomic signature reflecting the activated state of ERRa,
we used the best characterized ERRa coregulator, PGC-1a, as
a protein ligand to activate ERRa for this analysis. Because
PGC-1a coactivates a number of transcription factors, we used
the previously described ERR-selective derivative of PGC-1a
(PGC-1a 2x9) and a mutant form unable to interact with the NRs
(PGC-1a L2L3M) to capture the gene expression profiles repre-
senting ‘‘highERRa activity’’ and ‘‘lowERRa activity’’ states (Gail-
lard et al., 2006). The experiment was performed ten times to
generate independent biological replicates. The ERRa-regulated
genesetwasdefinedusing the followingcutoffs: foldchange (1.4-
fold), p value in pairwise t tests (0.001 before adjustment for
multiple comparisons) and proportion of ‘‘present’’ calls (20% in
each treatment group). The resulting ERRa-regulated gene set
consisted of 448 probe sets, corresponding to 354 unique genes.
To assess the clinical relevance of this gene set, we explored
the expression patterns of these genes in available breast cancer
clinical data sets using unsupervised hierarchical clustering. As
shown in Figure 1A, patient samples within the GSE2034 data
set partitioned into two branches of approximately the same
size based on the expression patterns of these ERRa-regulated
genes. Interestingly, patients in the right branch have shorter
relapse-free survival (RFS) compared with patients in the left
branch (Figure 1B). A similar observation was made when we
analyzed an additional data set, GSE4922 (Figures 1C and 1D).
We next wanted to know if the clinically distinct groups of patient
samples shared a coordinate regulation of defined sets of genes.
Thus, we performed unsupervised clustering of probe sets in
GSE2034 and fixed the order of probe sets in GSE4922 to match
that in GSE2034 to identify the common regulatory patternsancer Cell 20, 500–510, October 18, 2011 ª2011 Elsevier Inc. 501
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Figure 2. Correlations between Posterior Probabilities of ERRaActivation (as predicted by the cluster 3 classifier) and Relapse-Free Survival
in Seven Clinical Data Sets
‘‘Low ERR’’ and ‘‘High ERR’’ groups represent tumor samples with the posterior probability of ERRa activation lower than the mean and higher than the mean for
that data set. Significance was determined by log rank test. The predictability of cluster 3 ERRa classifier was validated in two independent data sets (Figure S2).
See also Tables S1 and S2.
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ERRa Is a Therapeutic Target in Breast Canceracross data sets. Four major clusters of coregulated genes were
identified, with some groups of genes demonstrating clear core-
gulation in distinct patient groups. We next determined whether
certain groups of genes carry more weight in partitioning the
patient samples into clinically distinct groups than others. To
this end, an unsupervised clustering of the samples was per-
formed to determine the ability of the genes within each cluster
to classify patient samples into groups with different clinical
outcomes. Only cluster 3 was found to retain the full capacity
of the larger, 448 probe set signature to distinguish between
patients with better or worse prognosis (Figure S1, available on-
line), while gene clusters 1, 2, and 4 do not have predictive values
(data not shown). Based on these observations, we hypothe-
sized that the genes within cluster 3 are potentially themost rele-
vant to patient outcome.
Although the genes from cluster 3 could be used to classify
patients into two separate groups, this analysis does not specify
whether tumors in the right branch, which represent worse prog-
nosis, have high or low ERRa activity. In order to address this
question, we utilized binary regression modeling to ascribe
a numerical value reflecting the estimated ERRa activity (using502 Cancer Cell 20, 500–510, October 18, 2011 ª2011 Elsevier Inc.the cluster 3 genes) to each patient sample and then tested the
correlation between this estimated activity and available clinical
endpoints. The details of this method have been described else-
where (Bild et al., 2006; Pittman et al., 2004) and the list of probe
sets comprising the cluster 3 is shown in Table S1. Briefly, binary
regression is a statistical method for classifying each sample
within the test (clinical) data set into one of the following two
phenotypic classes: ‘‘low ERRa activity’’ and ‘‘high ERRa
activity.’’ The phenotypic classes are defined by the training
data set, in this case, the expression values of ERRa-regulated
cluster 3 genes obtained from hMEC cells overexpressing
PGC-1a L2L3M or PGC-1a 2x9, providing the low (p = 0) and
high (p = 1) boundaries, respectively. It should be noted that for
this analysis, the estimated probability does not reflect the overall
activity of ERRa, but rather, the aspect of ERRa activity manifest
by the genes included in the classifier. For comparative pur-
poses, we also generated classifiers using the probe sets within
clusters 1, 2, and 4. The results of this analysis demonstrated
that the tumors with elevated ERRa activity, as defined by cluster
3 genes, correlatedwith shorter RFS in 5 out of 7 clinical data sets
tested (Figure 2). Analysis of two additional data sets produced
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Figure 3. The Sensitivity of Breast Cancer Cells to
ERRa Antagonist Correlates with Their Intrinsic
Cluster 3 ERRa Activity
Seventeen breast cancer cell lines with predicted high,
medium, and low levels of ERRa activity were treated with
an ERRa antagonist XCT790 and their growth inhibitory
responses (% inhibition) to these compounds were plotted
against the ERRa activity (average med p) of each cell line
predicted using gene expression data derived from each
cluster defined in Figure 1. Linear regression and p values
were determined using the GraphPad Prism software. The
percent inhibition was presented asmean ± SEM from four
independent experiments.
See also Tables S3 and S4 and Figure S3.
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ERRa Is a Therapeutic Target in Breast Cancerdiscordant results; we hypothesize that this is due to unusually
high RFS rates for patients with advanced (G3) disease in these
data sets compared with G1-G2 patients. Our analysis indi-
cates that Cluster 3 ERRa activity tends to be elevated in higher
grade tumors, which usually carry more negative prognosis
(data not shown). Aspects of ERRa activity predicted by classi-
fiers derived from clusters 1, 2, and 4 did not track with RFS
(data not shown). Also of interest, gene set enrichment analysis
based on expression correlation networks indicated that both
the expression of the cluster 3 signature, and individual genes
within this signature most strongly correlate with the expression
of numerous markers of proliferation, as well as gene sets char-
acteristic of undifferentiated tumor type, and c-MYC and EZH2
activation (Table S2).
Based on these observations, we concluded that the regula-
tion of genes within cluster 3 by ERRa is likely to reflect the
specific aspect of its activity that is most relevant to tumor
pathology.
The Intrinsic ERRa Activity of Breast Cancer Cells
Correlates with Their Sensitivity to ERRa Antagonists
Given that ERRa activity, as determined by the cluster 3-based
classifier, predicts cancer progression, it was of interest to see
if (1) the same activity was manifest in cellular models of breast
cancer and (2) ERRa activity could be used to predict phenotypic
responses to treatment with currently available antagonists of
this receptor. To this end, we determined the intrinsic ERRa
activity using the cluster 3 gene signature in a panel of breast
cancer cell lines using two published microarray data sets (Table
S3)(Bild et al., 2006; Neve et al., 2006). Seventeen cell lines that
were randomly selected from low,medium, and high ERRa activ-
ities were evaluated for their sensitivity to the well-characterized
ERRa antagonist XCT790 (Willy et al., 2004). In this manner, it
was determined that the sensitivity of breast cancer cell lines
to XCT790 correlates with their intrinsic ERRa activity, in that
cells with higher ‘‘cluster 3’’ ERRa activity are more sensitive to
XCT790-induced inhibition of cell growth (r2 = 0.3096, p =
0.0203) (Figure 3). Notably, ERRa activity predicted using cluster
1, 2, and 4 genes did not correlate with sensitivity to XCT790Cancer Cell 20, 50(Figure 3, Figure S3, and Table S4). Taken
together, these data indicate that the specific
aspect of ERRa activity reflected in the expres-
sion of the cluster 3 genes is important in breast
cancer pathology and provides a strong ratio-nale for therapeutic targeting of the ERRa signaling axis in breast
cancer.
PGC-1b Is an Important ERRa Coregulator in Breast
Cancer Cells
It is generally believed that posttranslational modifications and/
or cofactor availability constitute the main regulatory mecha-
nisms by which ERRa activity is modulated in cells. Specifically,
it has been demonstrated that both PGC-1a and PGC-1b
robustly enhance ERRa activity when assayed on reporter genes
and regulate overlapping repertoires of endogenous ERRa target
genes. To determine which of these cofactors are important for
ERRa activity in breast cancer cells, we assessed the expression
profiles of PGC-1a, PGC-1b, and PPRC1, a third member of the
PGC-1 subfamily of coregulators in a panel of breast cancer cell
lines. These studies revealed that PGC-1a mRNA expression
was limited to a few cell lines but that all of the cell lines examined
express both PGC-1b and PPRC1. Furthermore, it was noted
that the expression of PGC-1b, but not PGC-1a or PPRC1,
correlated with the expression of ERRa (Figure 4A). These data
suggest that within the context of breast cancer, PGC-1b is likely
to be the most relevant ERRa coactivator. However, PGC-1a
expression can be acutely regulated by nutrient status and envi-
ronmental stimuli (e.g., fasting, cold, and exercise), and thus we
cannot rule out the possibility that this coactivator may be
induced and regulate ERRa activity in breast cancer cells under
certain conditions. Hence, we next determined if the expression
of PGC-1b is important for ERRa activity in breast cancer cells.
Four different siRNAs targeting PGC-1b and one targeting
ERRa, as well as mock and relevant negative control siRNAs
were transfected into SKBR3 cells, a cell line exhibiting elevated
PGC-1b expression and high ERRa activity. The knockdown effi-
cacy of the respective genes was verified at both the RNA (not
shown) and protein levels (Figure 4B, bottom panel). Using this
approach, we demonstrated that knockdown of PGC-1b led to
a decreased expression of the cluster 3 ERRa target genes (Fig-
ure 4B, top panel). Furthermore, knockdown of either ERRa or
PGC-1b leads to significant retardation of cell growth (Figure 4C).
The effects of PGC-1b knockdown on the proliferation of addi-
tional cell lines were analyzed (Figure S4D and Table S5).0–510, October 18, 2011 ª2011 Elsevier Inc. 503
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Figure 4. PGC-1b Is Important for Maintaining ERRa Activity in
Breast Cancer Cells
(A) RNA from 19 breast cancer cell lines was harvested and the expression of
ERRa, PGC-1b, PGC-1a, and PRC-1 was assessed by qPCR. The relative
expression values of each gene of interest in SKBR3 cells were set as 1. The
data shown are representative of two independent experiments. Correlation
analysis was performed using GraphPad Prizm software.
(B) The expression of ERRa target genes in SKBR3was assessed following the
knockdown of ERRa (siERRa) or PGC-1b (siPGC1b A, C, D, and E). Control
siRNA (low31, med483), mock transfection (mock) and DMSO treatment were
included as negative controls. XCT790 treatment (10 mM) was used as a
positive control. The data shown are representative of three independent
experiments. The right panel shows the western blot analysis demonstrating
the knockdown of ERRa and PGC-1b at the protein levels. GAPDH was used
as a loading control. ‘‘siE’’ denotes siERRa.
(C) SKBR3 cells were transfected as in (B) and seeded in 96-well plates. Cells
were harvested 1, 3, 5, 7, 9, and 11 days after transfection and cell numbers
were determined by staining with the DNA dye Hoechst 33258. The data
shown are representative of three independent experiments.
See also Figure S4 and Table S5.
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ERRa Is a Therapeutic Target in Breast CancerAlthough it is impossible to achieve complete or equivalent
knockdown of ERRa and PGC-1b in every cell line, the data
showed that cell lines with high ERRa cluster 3 gene expression
tend to be more sensitive to PGC-1b knockdown. We further
verified that PGC-1b-activated ERRa induced cluster 3 gene
expression similar to that activated by PGC-1a in breast cancer
cells (Figures S4A–S4C). Together, these data imply that PGC-1b
is a major regulator of ERRa activity in breast cancer cells.
Definition of the Signaling Pathways that Regulate
the PGC-1b/ERRa Axis
The next step in this study was to define the pathways that were
responsible for regulating the expression and/or activity of PGC-504 Cancer Cell 20, 500–510, October 18, 2011 ª2011 Elsevier Inc.1b/ERRa axis. To this end, we undertook a chemical genomic
approach to identify signaling modulators that impacted ERRa
activity in breast cancer. Specifically, using the cluster 3 ERRa-
regulated genes we queried the Connectivity Map (cmap)
(Lamb et al., 2006). Developed by the Broad Institute, this re-
source is essentially a repository ofmicroarray data from sentinel
cell lines treated with over 1300 bioactive compounds including
those currently used in the clinic. Our query of the cmap identi-
fied several classes of compounds that had gene expression
profiles that negatively correlated with the expression of the
ERRa signature. Among the most interesting compounds impli-
cated in this manner were the phosphatidylinositol 3-kinase
(PI3K) inhibitors wortmannin and quinostatin (Table S6). Wort-
mannin was used to verify the cmap results in SKBR3 cells. It
was determined that wortmannin was as effective as XCT790
at inhibiting ERRa target gene expression (Figure 5A). Given
that PCG-1b is important for ERRa activity, we tested the possi-
bility that PI3K inhibitors like wortmannin may affect ERRa
activity indirectly by regulating the expression of this coactivator.
Indeed, treatment with wortmannin dramatically reduced the
expression of PGC-1b (Figure 5B). Similar results were obtained
in cells treated with the more selective PI3K inhibitor LY294002
or the Akt inhibitor GSK716166B (compound 4 described in
(Vlahos et al., 1994; Woods et al., 2006)). In contrast, the
mitogen-activated protein kinase (MAPK) inhibitor U0126 was
without effect (Figure 5C). These results suggest that PI3K and
its downstream target Akt are important for the expression of
PGC-1b. This finding is of particular interest as it has been sug-
gested previously that effector(s) downstream of Her2, including
PI3K and MAPK, can phosphorylate and regulate ERRa activity
(Ariazi et al., 2007). However, we have mapped and mutated
the putative phosphorylation sites within ERRa and have found
that the resultant proteins are indistinguishable from the wild-
type receptor with respect to their ability to activate target
gene transcription (unpublished data). Therefore, it is likely that
the major impact of PI3K signaling on ERRa activity results
from its ability to upregulate the expression of PGC-1b. Conse-
quently, it was important to define (1) the processes upstream
of PI3K that impacted PGC-1b expression and (2) how PI3K/
AKT activation resulted in an upregulation of PGC-1b mRNA
and protein.
To examine the role of Her2 in PGC-1a/ERRa signaling, the
expression of the cluster 3 genes was assessed in cell lines
where Her2 is amplified (AU565, SKBR3 and BT474 cells) and
a control cell line (BT483), following treatment with the Her2/
EGFR dual inhibitor GW2974 (Rusnak et al., 2001). Not surpris-
ingly, we observed quantitative downregulation of IDH3A and
several ERRa target genes by GW2974 (Figure 6 and data not
shown). Importantly, the expression of PGC-1b was also de-
creased following GW2974 treatment (Figure 6). In contrast,
PGC-1a expression was undetectable in SKBR3 and AU565
cells, and although it is expressed in BT474 and BT483 cells, its
expression was not altered by treatment with GW2974. Of note,
the expression level of an unrelated cofactor SRC-2 was not
significantly changed upon treatment. The involvement of Her2
signaling pathway in the regulation of PGC-1b expression was
further confirmed using an additional Her2 inhibitor (Figure S5).
To define the mechanism(s) by which the Her2 signaling
impacts PGC-1b expression in breast cancer cells, we used
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Figure 5. PI3K Inhibitors Attenuates ERRa Activity
in Breast Cancer Cells
(A) SKBR3 breast cancer cells were treated with vehicle, 5
and 10 mM XCT790, or 1 and 2 mM wortmannin for 24 hr.
RNA was harvested and the expression of ERRa target
genes was analyzed by qPCR. Ward hierarchical analysis
and heat maps were generated using the JMP software.
(B) SKBR3 cells were treated as in (A) and the expression
of PGC-1b was analyzed by qPCR.
(C) SKBR3 cells were treated with 20 mMLY294002, 10 mM
U0126, or 0.2 mM of the Akt inhibitor GSK716166B for
24 hr. RNA was harvested and the expression of PGC-1b
was analyzed by qPCR. 36B4 was used as an internal
normalization control for each sample and the relative
expression of each gene in compound- versus DMSO-
treated samples was expressed as fold induction ± SD.
The data shown are representative of at least three inde-
pendent experiments.
See also Table S6.
Cancer Cell
ERRa Is a Therapeutic Target in Breast CancerMCF7 cells, as Her2 is not overexpressed in these cells, but its
signaling pathway can be activated by treatment with heregulin
(HRG). In addition, since our data indicate that PI3K is important
for PGC-1b expression, it was of interest to examine whether
activation of the insulin-like growth factor 1 (IGF-1) receptor sig-
naling axis, a mechanism by which some breast cancer cells
circumvent the inhibition by Her2 inhibitors (Lu et al., 2001), leads
to PGC-1b upregulation. As shown in Figures 7A and 7B, the
expression of PGC-1b at both the mRNA and protein levels
was induced in MCF7 cells following treatment with either HRG
or IGF-1. HRG binds ErbB3 or ErbB4, which then dimerizes
with other members of the ErbB/EGFR family, including Her2,
and activates both the MAPK and PI3K signaling cascades. On
the other hand, IGF-1 binding to the IGF-1 receptor preferentially
activates the PI3K pathway. To further confirm that the PI3K
pathway is responsible for the induction of PGC-1b by these
two growth factors, inhibitors of MAPK and PI3K/Akt pathways
as well as the inhibitors of the EGFR/ErbB2 and IGF-1R were
used. Not surprisingly, we found that the dual EGFR/ErbB2
inhibitor GW2974 blocked the induction of PGC-1b by HRG
but not that induced by IGF-1 (Figure 7C). Conversely, the
IGF-1R receptor inhibitor ADW742 (Martins et al., 2006) selec-
tively blocked the induction of PGC-1b by IGF-1 but not that
induced by HRG. As predicted, only the inhibitors of the PI3K
pathways (LY294002 and the Akt inhibitor GSK716166B), but
not those of the MAPK pathway (U0126, PD98059) blocked the
induction of PGC-1b by both HRG and IGF-1 (Figure 7C and
data not shown). Additional inhibitors for each of the kinases
implicatedwereused toconfirmthese results (FiguresS5andS6).
C-MYC Regulates the Expression of PGC1-b in Breast
Cancer Cells in Response to Her2/IGF-1 Activation
It has been shown previously that hypoxia downregulates
PGC-1b mRNA in renal clear cell carcinoma cells by inducing
MXI1, a repressor of C-MYC activity (Zhang et al., 2007).Cancer Cell 20, 50Because both Her2 and IGF-1 signaling have
been shown to regulate C-MYC mRNA and/or
protein stability, we hypothesized that the in-
crease in PGC-1b mRNA by these growth
factors could be mediated by C-MYC. A timecourse study revealed a rapid induction of PGC-1b mRNA
following treatment of cells with either HRG or IGF-1 (Figure 8A).
However, under the same conditions, treatment with HRG but
not IGF-1 resulted in an induction of C-MYC mRNA. In contrast,
it was observed that there is a significant increase in C-MYC
protein expression following both HRG and IGF-1 treatment,
an effect that precedes the induction of PGC-1bmRNA (Figures
8A and 8B). To definitively demonstrate the involvement of
C-MYC in the regulation of PGC-1b by HRG and IGF-1, we pre-
treated cells with an inhibitor of C-MYC, 10058-F4, which blocks
the C-MYC/Max heterodimerization (Lin et al., 2007; Wang et al.,
2007). As shown in Figure 8C, 10058-F4 efficiently inhibited the
induction of PGC-1bmRNA by both HRG and IGF-1 (Figure 8C).
Importantly, 10058-F4 also abolished the induction of PGC-1b
protein levels by HRG and IGF-1, confirming that the induction
of PGC-1b protein by these growth factors is a transcriptional
event requiring C-MYC activity. Additionally, overexpression of
C-MYC led to increased PGC-1b expression whereas depletion
of C-MYC, using siRNA, resulted in the expected decrease in the
expression of this coregulator (Figure S7). Further, using a chro-
matin immunoprecipitation assay (ChIP), we demonstrated that
C-MYC is prebound to the two previously described C-MYC
binding sites within intron 1 of PGC-1b (Zhang et al., 2007).
Importantly, treatment with both HRG and IGF-1 further
enhanced the recruitment of C-MYC to this region (Figure 8D).
Taken together, these data indicate that C-MYC serves as
a conduit for signaling events initiated at the membrane, facili-
tating PGC-1b expression and the induction of ERRa transcrip-
tional activity.
DISCUSSION
We believe that this work will have a near term clinical impact as
it provides a mechanism to stratify tumors based on their ERRa
activity. The finding that the ability of an ERRa antagonist to0–510, October 18, 2011 ª2011 Elsevier Inc. 505
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Figure 6. Her2 Signaling Pathway Regulates ERRa Activity Partially through Modulating the Expression of PGC-1b
SKBR3, BT474, and AU565 cells (Her2-amplified) and BT483 breast cancer cells (not Her2-amplified) were treated with vehicle or 0.5 and 1 mMof the dual EGFR/
Her2 inhibitor GW2974 for 24 hr. RNAwas harvested and the expression of IDH3A (ERRa target gene),PGC-1b, PGC-1a, and an unrelated coactivatorSRC2were
analyzed by qPCR. 36B4 was used as an internal normalization control for each sample and the ratio of each gene in compound- versus DMSO-treated samples
was expressed as relative expression (the expression values of DMSO treated samples of each cell line was set to 1). The data shown are average ±SEM of three
independent experiments. ‘‘ND’’ stands for not detectable. See also Figure S5.
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ERRa Is a Therapeutic Target in Breast Cancerinhibit cell growth tracks with the activity of ERRa in cancer cells
provides a strong rationale for targeted therapy of tumors in
which this receptor is transcriptionally active. Additionally, the
finding that the ERRa signaling axis is downstream of Her2 and
IGF-1R suggests that interventions that include the combined
administration of an ERRa antagonist and inhibitors of Her2/
IGF-1R signaling may have clinical utility.
Clearly, the cluster 3 gene signature does not represent the full
and unbiased spectrum of ERRa activity. Rather, it represents
a facet of ERRa activity that is relevant to patient prognosis.
Indeed, we have determined that cluster 3, enriched inmetabolic
genes, is manifest in tumors that also express genes associated
with highly proliferative phenotypes (Table S2). By leave-one-out
strategy, we cannot pinpoint an individual gene that would ex-
plain the full predictive capacity of this cluster (data not shown),
suggesting this activity is the sum of contributions of multiple
genes within this cluster. However, our data lend credibility to
the hypothesis that cluster 3 reflects a sum of genes involved in
oxidative phosphorylation and TCApathways,whose expression
is coordinately elevated by ERRa signaling to satisfy the elevated
energy demands of a rapidly dividing tumor cell. However, we
cannot definitively conclude that cluster 3 genes are respon-
sible for all the phenotypes observed. It is also possible that506 Cancer Cell 20, 500–510, October 18, 2011 ª2011 Elsevier Inc.ERRa-regulated genes contained within other clusters may
also contribute significantly to thepathogenesis of breast cancer.
In addition to validating a role for ERRa in the pathogenesis of
breast tumors, the results of this study highlight additional path-
ways that can be targeted for the treatment of tumors in which
this receptor is active. For instance, the set of ERRa regulated
genes generated from cluster 3 is most predictive of unfavorable
outcome, and this cluster is enriched in genes coding enzymes
of TCA cycle and oxidative phosphorylation pathway (6 and 20
genes, respectively, by GO annotations). Although a strong link
between cellular metabolism and cancer has been established,
most efforts in this area were directed toward an understanding
of the processes that regulate aerobic glycolysis and how these
could be targeted for therapy. More recently, however, it has
become clear that metabolic pathways that fulfill the high
demand for biosynthetic intermediates by rapidly dividing cancer
cells are also likely to be useful points for therapeutic interven-
tion. Of note in this regard is the observation that inhibition of
fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), ATP
citrate lyase, or pyruvate dehydrogenase kinase (PDK) can nega-
tively inhibit the growth of tumors (Bauer et al., 2005; Beckers
et al., 2007; Hatzivassiliou et al., 2005; Kuhajda et al., 2000; Pa-
thania et al., 2009; Pizer et al., 1996). Indeed, several drugs
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Figure 7. Activation of Her2 or IGF-1R Signaling Pathways Enhances
the Expression of PGC-1b
(A) MCF7 breast cancer cells were serum starved for 24 hr and then treated
with vehicle or 100 ng/ml of the indicated growth factors for 8 hr. RNA was
harvested and the expression of PGC-1b was analyzed by qPCR.
(B) MCF7 cells were treated as in (A) and whole-cell extracts were collected 8
and 25 hr after growth factor stimulation. Western immunoblot was used to
determine the expression of PGC-1b. GAPDH was used as a loading control.
(C) MCF7 cells were serum starved and pretreated for 1 hr with various kinase
inhibitors followed by 8 hr treatment with vehicle, heregulin, or IGF-1. RNAwas
harvested and the expression of PGC-1bwas analyzed by qPCR. For all qPCR
analysis, 36B4 was used as an internal normalization control for each sample
and the relative expression of each gene in treatment versus vehicle-treated
samples was expressed as average fold induction ±SD. The data shown are
representative of at least three independent experiments.
See also Figure S6.
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ERRa Is a Therapeutic Target in Breast Cancertargeting the TCA cycle and OXPHOS are currently being
evaluated as treatments for various cancers (Pathania et al.,
2009). Thus, in addition to ERRa antagonists, agents that inhibit
these pathways are likely to have therapeutic efficacy in tumors
exhibiting high ERRa activity. Furthermore, we observed both
similarities and differences in the way the expression of each
of the four signatures correlates with patient survival. Based on
these observations we hypothesize that ERRamay have distinct
activities, some good and some bad for the tumor growth. It will
be interesting to see if pharmaceuticals targeting one aspect
(cluster 3 genes) of ERRa activity will be more beneficial than
targeting the overall ERRa activity in tumors manifesting high
ERRa activity. This result provided us with an impetus to explore
approaches that may enable the dissection of the distinct path-
ways regulated by this multifaceted receptor and to identify tools
with which to develop ‘‘pathway-selective modulators’’ of this
receptor.
Our ERRa signature was built based on the activity of ERRa
when it was activated by PGC-1a. Our subsequent analysis
has led us to conclude that the closely related coactivator
PGC-1b may be a more relevant coactivator for ERRa in breast
cancer cells. The expression of ERRa and PGC-1b correlate
very well in most commonly used breast cancer cell models
tested, and knockdown of PGC-1b interferes with ERRa targetCgene expression. Underscoring the importance of this finding
is the fact that the expression of PGC-1b is controlled by growth
factor signaling pathways, i.e., Her2, IGF-1R, and PI3K, the sig-
nificance of which in breast cancer and other tumors is well
established. We have observed statistically significant higher
Cluster 3 ERR signature scores in ErbB2-overexpressing sub-
type of tumors in one data set containing such information, but
not in the other (data not shown). Extremely small sample size
may have contributed to the latter observation. Furthermore,
we have demonstrated in this report that the ERRa coactivator
PGC-1b is a transcriptional downstream target of both Her2
and IGF-1R pathways, which converge on the transcription
factor C-MYC. Thus, it is likely that any manipulation that im-
pacts C-MYC expression and/or stability will effect PGC-1b
expression and, ultimately, ERRa transcriptional activity. There-
fore, we expect that the PGC-1b/ERRa signaling axis will be acti-
vated inmore than just Her2-positive tumors and therefore we do
not expect Her2 status to always correlate with ERRa cluster 3
gene expression. For instance, the Wnt signaling pathway, also
frequently upregulated in tumors, has been shown to regulate
the transcription of C-MYC by inducing b-catenin/TCF/LEF (He
et al., 1998). Further, because of its ability to inhibit GSK3b, the
Wnt pathway may also regulate the stability of C-MYC protein
posttranslationally (Cook et al., 1996; Sears et al., 2000). Indeed,
we found that inhibition of GSK3b in MCF7 cells also led to
increased expression of C-MYC and PGC-1b (data not shown).
C-MYC is a proto-oncogene whose expression is dysregu-
lated in approximately 70% of human tumors. It is involved in
a diverse range of biological processes, including proliferation,
apoptosis, and differentiation. It also regulates ribosomal bio-
genesis to affect protein synthesis and influence glycolysis and
mitochondrial biogenesis to control cellular metabolism (Li
et al., 2005). The fact that PGC-1b is a direct target of C-MYC
raises the possibility that some of these well-established func-
tions of C-MYC may be mediated by PGC-1b and ERRa. It has
been proposed that the ability of C-MYC to regulate both glycol-
ysis and mitochondrial activity confers upon cancer cells the
ability to both generate ATP and synthesize the synthetic inter-
mediates needed to sustain rapid cell proliferation (Gordan
et al., 2007). Our observation that the PGC-1/ERR-regulated
TCA cycle and OXPHOS genes track with unfavorable clinical
outcomes may reflect the need of more aggressive tumors to
produce biosynthetic intermediates, a hypothesis that is cur-
rently under investigation.
In summary, we have used a genomic approach to demon-
strate that high ERRa cluster 3 gene expression correlates with
unfavorable clinical outcomes in breast cancer. Furthermore,
we have provided evidence that compounds that antagonize
ERRa activity may have utility in the treatment of patients whose
tumors exhibit heightened ERRa activity. Thus, although an acti-
vating ligand for this receptor has not yet been identified, the
results of this study provide strong justification for the continued
pharmacological exploitation of this receptor.EXPERIMENTAL PROCEDURES
Chemicals
XCT790, GSK716166B, and ADW742 were gifts from W. Zuercher
(GlaxoSmithKline, RTP, NC). LY294002 was purchased from Alexisancer Cell 20, 500–510, October 18, 2011 ª2011 Elsevier Inc. 507
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Figure 8. C-MYC Integrates IGF-1 and Her2
Signaling to Activate the Transcription of PGC-1b
(A and B)MCF7 breast cancer cells were serum starved for
24 hr and then treated with vehicle or 100 ng/ml of the
indicated growth factors for different time points. RNA and
protein were harvested. The expression of PGC-1b and
C-MYC transcripts was analyzed by qPCR (A) and the
expression of C-MYC proteins was assessed by western
immunoblots (B).
(C)MCF7cellswereserumstarvedandpretreatedwith10or
25 mM of the C-MYC inhibitor 10058-F4, followed by 8 hr
treatment with vehicle, heregulin (HRG), or IGF-1. RNA and
whole-cell extracts were collected and the expression of
PGC-1b RNA and protein, as well as C-MYC protein was
analyzed. For all qPCR analysis, 36B4 was used as an
internal normalization control for each sample and the
relativeexpressionofeachgene in treatmentversusvehicle-
treated samples was expressed as fold induction ±SD. The
data shown are representative of at least three independent
experiments.
(D) MCF7 cells were serum starved and treated with
vehicle, HRG, or IGF-1 for 90 min, and the chromatin was
crosslinked with formaldehyde. Chromatin immunopre-
cipitation was performed using either an IgG control or an
antibody that recognizes C-MYC. Precipitated chromatin
was reverse crosslinked and quantitated by qPCR using
primers spanning the putative C-MYC binding sites in the
intron 1 of PGC-1b.
See also Figure S7.
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ERRa Is a Therapeutic Target in Breast CancerBiochemicals (Plymouth Meeting, PA), wortmannin from Cayman Chemical
(Ann Arbor, MI), U0126 from Promega (Madison, WI), and GW2974 and
10058-F4 from Sigma (St. Louis, MO). Heregulin, EGF, and IGF-1 were pur-
chased from Peprotech (Rocky Hill, NJ) and Actinomycin D from Calbiochem
(La Jolla, CA). Oligonucleotideswere synthesized by either IDTDNA (Coralville,
IA) or Sigma-Genosys (St. Louis, MO). siRNAs were purchased from Invitrogen
(San Diego, CA). Kinase inhibitors were used at the following concentrations
unless otherwise specified: 1 mM GW2974, 10 mM LY294002, 10 mM U0126,
0.2 mM GSK716166B, and 0.5 mM ADW742.
Generation of ERRa Signature in hMEC Cells
Primary human mammary epithelial cells were cultured in MEBM (Cambrex,
East Rutherford, NJ) with MEGM bullet kit supplemented with 5 mg/ml
transferrin and 105 M isoproterenol. To generate the ERRa signature,
hMECs were serum starved for 36 hr followed by infection with MOI =
150 of adenoviruses expressing PGC-1a 2x9 or PGC-1a L2L3M. The gener-
ation of variant PGC-1a viruses were described previously (Gaillard et al.,
2006). Comparable expression levels of the two PGC-1a variants were veri-
fied by western blot analysis (data not shown). RNA was collected 16 hr
after infection and purified using QIAGEN RNeasy kit (Valencia, CA). Ten
biological replicates of each virus infection were collected. Probe prepara-
tion and hybridization to the Hu133A2.0 Affymetrix High Throughput Array
system (Affymetrix, Santa Clara, CA) were performed by the Duke microar-
ray facility.
Cell Culture
All cell lines were obtained from ATCC (Manassas, VA) and maintained in
a 37C incubator with 5% CO2. SKBR3, BT474, AU565 were cultured in
RPMI, and MCF7 cells were cultured in DMEM/F12 (Invitrogen). All media
were supplemented with 8% fetal bovine serum (Sigma), 1 mM sodium pyru-
vate, and 0.1 mM nonessential amino acids (Invitrogen). For serum508 Cancer Cell 20, 500–510, October 18, 2011 ª2011 Elsevier Inc.starvation, MCF7 cells were split into regular media for
2 days, washed with serum and phenol-red free DMEM/
F12 then placed in the same media for 24 hr before
growth factor treatments. For kinase inhibitor experi-
ments, serum starved cells were pretreated with the indi-cated concentrations of compounds for 1 hr before HRG or IGF-1 (100 ng/ml)
stimulation.
Gene Expression Analysis
RNA was purified using the Aurum RNA kit (Bio-Rad Laboratories, Hercules,
CA). Detailed protocol and primers used are listed in Supplemental
Experimental Procedures. Fold induction was calculated using the 2 -DDCt
method and 36B4 was used as the normalization control. Data shown are
representative of at least three independent experiments. Clustering heat-
maps were generated by Ward hierarchical clustering using the JMP software
(SAS Institute, Cary, NC).
Proliferation Assay
SKBR3 (5000 cells/well) were transfected using DharmaFECT1 (with 100 nM
siRNAs for ERRa, PGC-1b or controls [LowGC, MedGC, and mock]) and
seeded in 96-well plates containing regular RPMI. Cells were harvested 1, 3,
5, 7, 9, or 11 days after transfection and were assayed for DNA content using
Hoechst 33258 (Sigma) and the fluorescence was read at excitation 346 nm
and emission 460 nmusing a Fusionmicroplate reader (PerkinElmer,Waltham,
MA). Data shown are representative of three independent experiments.
Sensitivity to ERRa Antagonist
Breast cancer cells were cultured in RPMI, DMEM, or DMEM/F12 to
mimic conditions in which the microarray data sets were generated (Bild
et al., 2006; Neve et al., 2006). Detailed culture conditions are described in
Supplemental Experimental Procedures. For proliferation assays, cells were
seeded between 3000 and 7500 cells/well in triplicates in 96-well plates for
2 days so that cells were about 30%–40% confluent at the time of treatment.
Half of the media (50 ml) was removed and 50 ml of fresh media containing 23
concentrations of compounds was added every other day for a total of three
treatments. Cells were harvested on day 6 and cell number was determined
Cancer Cell
ERRa Is a Therapeutic Target in Breast Cancerby DNA content using Hoechst 33258 DNA dye. Percent inhibition was cal-
culated as 100*[1-(fluorescence of compound-treated cells)/(fluorescence of
DMSO treated cells)]. The percent response was plotted against the average
medium p values (probability of ERRa activation) determined for each cell
line using each ERRa-regulated gene clusters. Correlation and statistical anal-
yses were done using the Prism software (GraphPad, La Jolla, CA). Data
shown was the average of four independent experiments.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation assay was performed as previously described
(Norris et al., 2009). Detailed protocol and primers used are included in the
Supplemental Experimental Procedures.
Analysis of global Gene Expression
Microarray data obtained in hMEC cells were analyzed using dCHIP software
(Li and Wong, 2001). Model based expression indices were calculated on
log2-transformed data using PM-MM differences. Clustering was performed
by centroid linkagewith 1-correlation distancemetric; rows were standardized
by subtracting the row mean and dividing by standard deviation.
Predictive Modeling
The algorithm for predicting a pathway activity based on the expression data
from a set of responsive genes has been described previously (Bild et al.,
2006; West et al., 2001). Detailed protocol see Supplemental Experimental
Procedures.
Survival Analysis
For determining the correlation between ERRa pathway activation and RFS,
clinical samples were ordered according to mean posterior probability of
ERRa activation and divided at the average value into two groups, ‘‘High
ERRa activity’’ and ‘‘Low ERRa activity.’’ Kaplan-Meyer survival analysis
was then performed comparing the RFS in the two groups. p values were
obtained from the Mantel-Cox test. Microarray data of clinical samples were
obtained from previously published patient de-identified data sets. The state-
ments of IRB approval were included in the cited original manuscripts.
ACCESSION NUMBERS
The hMEC microarray data have been deposited in GEO: GSE23061.
Supplemental Material
Supplemental Material includes Experimental Procedures, seven figures, six
tables and can be found online at doi:10.1016/j.ccr.2011.08.023.
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